Compare · HAYW vs TMO
HAYW vs TMO
Side-by-side comparison of Hayward Holdings Inc. (HAYW) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAYW and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.52B, about 57.0x HAYW ($3.06B).
- Over the past year, HAYW is down 0.7% and TMO is up 14.9% - TMO leads by 15.6 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 12 for HAYW).
- TMO has more recent analyst coverage (25 ratings vs 21 for HAYW).
- Company
- Hayward Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- $14.12+0.36%
- $469.56-0.67%
- Market cap
- $3.06B
- $174.52B
- 1M return
- -4.34%
- -1.03%
- 1Y return
- -0.67%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 12
- 17
- Recent ratings
- 21
- 25
Hayward Holdings Inc.
Hayward Holdings, Inc. operates as a designer, manufacturer, and marketer of various pool equipment and associated automation systems. The company offers a range of pool equipment, including pumps, filters, heaters, automatic cleaners, sanitizers, controls, and LED lights, as well as industrial thermoplastic valves and process liquid control products for in-ground residential pools, above ground pools, and commercial pools. Hayward Holdings, Inc. is based in Berkeley Heights, New Jersey.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest HAYW
- SVP, CLO, Corporate Secretary Canning Susan M. was granted 71,074 shares, increasing direct ownership by 68% to 174,911 units (SEC Form 4)
- President and CEO Holleran Kevin exercised 52,389 shares at a strike of $1.40 and sold $722,366 worth of shares (52,389 units at $13.79) as part of a pre-agreed trading plan (SEC Form 4)
- Director Ward Edward D was granted 10,608 shares, increasing direct ownership by 27% to 50,055 units (SEC Form 4)
- Director Silber Lawrence Harris was granted 10,608 shares, increasing direct ownership by 19% to 67,407 units (SEC Form 4)
- Director Brown Kevin D. was granted 10,608 shares, increasing direct ownership by 0.33% to 3,221,432 units (SEC Form 4)
- Director Keating Ronald C was granted 10,608 shares, increasing direct ownership by 22% to 59,171 units (SEC Form 4)
- Director Soucy Arthur L was granted 10,608 shares, increasing direct ownership by 21% to 60,075 units (SEC Form 4)
- Director Felice Stephen J was granted 16,094 shares, increasing direct ownership by 5% to 364,333 units (SEC Form 4)
- Director Walker Lori A was granted 10,608 shares, increasing direct ownership by 22% to 59,407 units (SEC Form 4)
- Director Dayhoff Diane was granted 10,608 shares, increasing direct ownership by 23% to 57,407 units (SEC Form 4)
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)